Sign in Subscribe
Hospitals

Loma Linda University Medical Center--Murrieta Offers Revolutionary Tricuspid Valve Replacement with the Edwards EVOQUE Device

Strategic Insights

— 2 min read

Doctors at Loma Linda University Medical Center--Murrieta are now performing tricuspid valve replacement using the Edwards EVOQUE device, a minimally invasive treatment that helps heart patients regain quality of life with improved energy due to effective blood flow. The EVOQUE device is a transcatheter valve replacement to help patients with severe tricuspid valve regurgitation, a condition where deoxygenated blood isn't fully being pulled into the heart. This breakthrough treatment is an alternative to open-heart surgery and is now available at one of approximately 20 hospitals in the nation, including Loma Linda University Medical Center--Murrieta.

Key Takeaways:

  • The Edwards EVOQUE device is a minimally invasive treatment that helps heart patients regain quality of life with improved energy due to effective blood flow.
  • The EVOQUE device is a welcomed addition to the field because doctors have historically had challenges treating the tricuspid valve, which is located on the right side of the heart.
  • Loma Linda University Medical Center--Murrieta is one of approximately 20 hospitals in the nation that now offers the EVOQUE procedure, made possible through a recent FDA approval.
  • The EVOQUE device is used to treat patients with severe tricuspid valve regurgitation, where deoxygenated blood isn't fully being pulled into the heart, causing fatigue, shortness of breath, leg swelling, and requiring hospitalizations for heart problems.
  • The procedure takes less than an hour and is delivered through a vein starting in the patient's groin, requiring only an echocardiogram to set the device in place.
  • Niraj Parekh, MD, an interventional cardiologist at LLUMC--Murrieta, says the EVOQUE device helps patients dramatically and reduces the need for hospitalizations and medications that can affect kidney function.
  • The tricuspid valve doesn't respond well to medications that have traditionally been prescribed to address issues stemming from problems with the left side of the heart.
  • The EVOQUE device has been shown to improve the quality of life for patients with severe tricuspid valve regurgitation, reducing the need for hospitalizations and medications.

Statistics:

  • Approximately 20 hospitals in the nation offer the EVOQUE procedure, including Loma Linda University Medical Center--Murrieta.
  • Over 100 hospitals were used as trial sites for the EVOQUE device during research.
  • The EVOQUE device is approved by the FDA for use in treating patients with severe tricuspid valve regurgitation.
  • The procedure takes less than an hour to complete.
  • The EVOQUE device is delivered through a vein starting in the patient's groin, requiring only an echocardiogram to set the device in place.

Sources:

  • Loma Linda University
  • Edwards EVOQUE device
  • FDA approval
  • LLUMC--Murrieta Heart & Vascular website
  • Contify.com

Read more